Gapping up
In reaction to earnings/guidance:
- AMRX +8.8% (Q1 guidance), AQN +7.2% (Algonquin Power & Utilities and American Electric Power (AEP) terminate Kentucky power transaction; AQN reaffirms guidance), MTB +3.4%, LIVN +3.3% (CEO Damien McDonald resigns; co also guides Q1 revs above consensus), GTX +2.3%, .
Other news:
- RXDX +69.7% (to be acquired by Merck (MRK) for $200.00 per share)
- PCVX +9.8% (Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24)
- AGEN +4.8% (receives Fast Track Designation for Botensilimab and Balstilimab in colorectal cancer)
- CLLS +3.4% (Presents Preclinical Data on TALEN-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting)
- MAXR +2.7% (receives majority of regulatory consents required for previously proposed acquisition by Advent International)
- OCUL +2.1% (to Present Pre-Clinical and Clinical Data at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting)
- PEBO +2% (receives all necessary regulatory approvals for the merger between Peoples and Limestone Bancorp (LMST) )
- AMX +2% (approved buyback program fund for the April 2023 -- April 2024 period of MXP$20,000,000,000)
- ME +1.8% (Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1)
- YY +1.7% (announces repurchase right notification for 0.750% convertible senior notes due 2025)
- SGML +1.5% (initiates production of green lithium)
- ARGX +1.4% (Argenx and Genmab (GMAB) enter partnership to advance antibody therapies in immunology and oncology)
Analyst comments:
- DXCM +2% (upgraded to Strong Buy from Outperform at Raymond James)
- BIIB +1.3% (upgraded to Overweight from Neutral at Piper Sandler)